- Home
- JVA vs APLM Comparison
JVA vs APLM Comparison
Compare JVA & APLM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JVA
- APLM
- Stock Information
- Founded
- JVA 1971
- APLM 2016
- Country
- JVA United States
- APLM United States
- Employees
- JVA N/A
- APLM N/A
- Industry
- JVA Packaged Foods
- APLM Blank Checks
- Sector
- JVA Consumer Staples
- APLM Finance
- Exchange
- JVA Nasdaq
- APLM Nasdaq
- Market Cap
- JVA 14.7M
- APLM 15.6M
- IPO Year
- JVA 2005
- APLM N/A
- Fundamental
- Price
- JVA $3.01
- APLM $0.16
- Analyst Decision
- JVA
- APLM Strong Buy
- Analyst Count
- JVA 0
- APLM 2
- Target Price
- JVA N/A
- APLM $4.25
- AVG Volume (30 Days)
- JVA 174.0K
- APLM 924.9K
- Earning Date
- JVA 10-11-2024
- APLM 08-14-2024
- Dividend Yield
- JVA N/A
- APLM N/A
- EPS Growth
- JVA N/A
- APLM N/A
- EPS
- JVA 0.20
- APLM N/A
- Revenue
- JVA $76,111,698.00
- APLM $2,101,000.00
- Revenue This Year
- JVA N/A
- APLM N/A
- Revenue Next Year
- JVA N/A
- APLM N/A
- P/E Ratio
- JVA $15.08
- APLM N/A
- Revenue Growth
- JVA 17.27
- APLM 70.54
- 52 Week Low
- JVA $0.67
- APLM $0.11
- 52 Week High
- JVA $3.88
- APLM $3.18
- Technical
- Relative Strength Index (RSI)
- JVA 55.27
- APLM 60.35
- Support Level
- JVA $3.00
- APLM $0.13
- Resistance Level
- JVA $3.74
- APLM $0.18
- Average True Range (ATR)
- JVA 0.32
- APLM 0.01
- MACD
- JVA -0.04
- APLM 0.00
- Stochastic Oscillator
- JVA 15.53
- APLM 65.52
About JVA Coffee Holding Co. Inc.
Coffee Holding Co Inc is engaged in the business of wholesale coffee operations, including manufacturing, roasting, packaging, marketing and distributing roasted and blended coffees for private labeled accounts and its own brands, and it sells green coffee. Its products include wholesale green coffee, private-label coffee, and branded coffee. The company sells its coffee products throughout the United States, Canada and certain countries in Asia.
About APLM Apollomics Inc.
Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.